



ASX RELEASE (8 AUGUST 2022)

## Director Resignation

Epsilon Healthcare Limited (ASX:EPN) (Epsilon or the Company) advises that Dr Rob Jenny has resigned as a director of the Company with effect from yesterday, 7 August 2022.

Dr Jenny has served as an Executive Director of the Company since August 2021 pursuant to an arrangement between the Company and Cannvalate Pty Ltd (Cannvalate) as part of securing broader strategic alignment between them.

The Company does not propose to consider the appointment of a new Cannvalate representative to the Epsilon Board of Directors at this time. The Company thanks Dr Jenny for his service to the Company over the past year.

Dr Jenny's Appendix 3Z is attached.

ENDS

ASX release authorised by the EPN Executive Management Committee.

For further information, please contact:



**Steven Xu**  
Executive Chairman  
e: [corporate@epsilonhc.com](mailto:corporate@epsilonhc.com)

**Sonny Didugu**  
Group Chief Operating Officer  
e: [coo@epsilonhc.com](mailto:coo@epsilonhc.com)

### **Epsilon Healthcare Limited (ASX: EPN) – [epsilonhealthcare.com.au](http://epsilonhealthcare.com.au)**

Epsilon Healthcare (ASX:EPN) is a diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere (the Southport Facility) and the Tetra Health clinic group. EPN has a strategic partnership with The Valens Company (NASDAQ: VLNS), a leading cannabis consumer products company with significant expertise in manufacturing cannabinoid based products, for operation and management of its Southport Facility.

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Epsilon Healthcare Limited
<b>ABN</b>	33 614 508 039

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Dr Robert Alexander Jenny
<b>Date of last notice</b>	1 August 2021
<b>Date that director ceased to be director</b>	7 August 2022

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Nil.

+ See chapter 19 for defined terms.

## Appendix 3Z

### Final Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> Note: Provide details of the circumstances giving rise to the relevant interest	<b>Number &amp; class of securities</b>
None.	N/A

#### Part 3 – Director's interests in contracts

<b>Detail of contract</b>	No interest in contracts.
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>No. and class of securities to which interest relates</b>	N/A

---

+ See chapter 19 for defined terms.